KAIST said yesterday: "Professor Jin Guangzhu from Harvard Medical School has successfully treated stem cell patients in clinic". After receiving master's and doctor's degrees from the Department of Life Sciences of Korea University of Science and Technology (KAIST), Professor Jin continued to conduct research in various parts of the United States. Ranked in the forefront of neuroscience and stem cell academic fields. This is the first time that iPS cells have been transplanted into patients with brain diseases, and the clinical treatment effect has been achieved.
What are iPS cells?
IPS cells can differentiate into nerve cells, blood cells, musculoskeletal cells and other cells that make up the human body, and are called "universal cells".
Kim has been approved by the US Food and Drug Administration (FDA) and has transplanted stem cells into two 69-year-old patients with Parkinson's disease twice since 20 17. The method is to transform the patient's skin cells to produce the neurotransmitter dopamine, and then inject it into the deep brain of the patient.
After examining the progress of PET/MRI images in the next two years, a paper was published in May. The patient showed no rejection of the immune system and recovered to the point where he could tie his shoelaces. Recovered the ability to swim or ride a bike. The patient undergoing surgery said that he had helped Professor Jin's research team focus on accelerating stem cell research and overcoming Parkinson's disease.
The success of these operations and clinical trials is not a short-term result. Stem cell therapy for Parkinson's disease must first transform the patient's somatic cells into stable stem cells, then differentiate into dopamine cells and transplant them into the brain. Professor Jin, who has been studying related technologies for 20 years, first developed the technology of making iPS cells from virus-free patient cells about 10 years ago. The method is applied to the animal model of Parkinson's disease, and the effectiveness of the method is verified. Professor Jin said: "We applied for FDA approval so that we can conduct clinical trials on more patients." "If the follow-up research progresses smoothly for more than 10 years, cell therapy will become another treatment for Parkinson's disease. It will be established as a universal treatment.
Note: This paper aims to introduce the frontier research progress. If you need the guidance of treatment plan, please go to a regular hospital.